• 1. Which statement best describes the pharmacologic rationale for targeting factor XIa (FXIa) rather than factor Xa or thrombin in stroke prevention for atrial fibrillation (SPAF)?*
  • 2. What was the key finding in the phase 3 OCEANIC-AF trial (asundexian vs. apixaban in AF) that led to early termination?*
  • 3. Which patient profile would most likely be considered a favorable candidate for an FXIa inhibitor over a DOAC for SPAF, should one become available with an appropriate efficacy/safety profile?*
  • 4. Which patient characteristic profile most strongly supports considering an FXIa inhibitor once available, based on data such as AZALEA-TIMI 71 (62-69% reduction in major/CRNM bleeding vs. rivaroxaban)?*
  • 5. A 79-year-old woman with AF, CHA2DS2-VASc score of 5 (CHA2DS2-VA=4), HAS-BLED score of 4, and a prior intracranial hemorrhage on warfarin has gone untreated for a year due to bleeding concerns. Which statement best reflects an evidence-based application of current data to her care?
  • 6. Based on the totality of phase 3 evidence (OCEANIC-AF, LIBREXIA-AF pending, AZALEA-TIMI 71, LILAC-TIMI 76), how should emerging FXIa inhibitor data currently inform the new paradigm discussion for SPAF?
  • What is your license?*

  • Please rate the extent to which this activity met the following objectives:

  • Learning Objectives
    Rows
  • Do you feel this activity was fair balanced and free of commercial bias?
  • This educational activity will result in a change in my role as a healthcare team member.
  • This educational activity will result in a change in my practice behavior.
  • Based on your participation in this activity, choose the statement(s) that applies to how your role as a healthcare team member will change:

  • Attestation to time spent on activity:

    AcademicCME designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits™, 0.75 CNE Contact Hours (Provider #P0491) or 0.75 CPE Contact Hours (0.075 CEUs) UAN # JA4008190-0000-26-018-L01-P.

    This program is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) for 0.75 hours of effective education time. AcademicCME is an EBAC® Accredited Provider since 2026.

  • Please select your credit type from the below:*

  • AcademicCME thanks you for your participation in this activity. All information provided improves the scope and purpose of our programs.

  • Should be Empty: